OsemwotaOmoiguiMD

Summary

• Sota Omoigui M.D. is medical director of the L.A. Pain Clinic in Hawthorne, California. He is board certified in Anesthesia with subspecialty certification in Pain Medicine. He has served as an adviser to the United States, FDA Advisory Committee on Anesthetics and Life Support Devices.His research work in Pain Pharmacology, Anesthetic Pharmacology, Inflammation and the Inflammatory response, has also greatly impacted the medical field. Dr Sota Omoigui is a bestselling author with drug handbooks published in six languages (Indonesian, Italian, Japanese, Malaysian, Polish and Portuguese), and used by pain specialists and anesthesiologists all over the world. In his seminal book titled: The Biochemical Origin of Pain and published in 2002, he proposed his theoretical law that the origin of pain is due to inflammation and the inflammatory response. His subsequent publication of his theory as a journal article in 2007 been cited as of this date by 415 medical publications in Google Scholar. In his 2002 theory, he demonstrated a clear association between migraine and the release of inflammatory mediator calcitonin gene-related peptide (CGRP) and substance P (SP). In 2019, seventeen years later, the US FDA approved members of a new class of drugs specifically designed to treat migraine by targeting calcitonin gene-related peptide (CGRP). Those drugs have been the greatest advance in the treatment of migraine. The Physics law of conservation of mass, as embodied in the equation of continuity states that, in any steady state process, the rate at which mass enters a system is equal to the rate at which mass leaves the system. Applying that law to injection procedures, Dr Omoigui has pioneered minimally invasive myofascial nerve block injection procedures utilizing a 30G 5/8 in needle to treat spinal pain and radiculopathy that hitherto required epidural injections with 3-5 inch needles. Thus advancing the utilization of spinal injections by PCPs, PAs and NPs.